Overview

An Open-Label Study of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia

Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of various doses and dosing intervals of aripiprazole lauroxil.
Phase:
Phase 1
Details
Lead Sponsor:
Alkermes, Inc.
Treatments:
Aripiprazole
Aripiprazole lauroxil